Clinical Trial

AK104 in Combination With AK112 Plus Chemotherapy(SOX/XELOX) as First-line Treatment for Advanced G/GEJ Cancer

Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
The goal of this study is to evaluate the safety, tolerability, pharmacokinetics (PK), immunogenicity, and anti-tumor activities of cadonilimab in combination with Ivonescimab plus chemotherapy as first-line therapy in adult subjects with HER2 negative、advanced or metastatic gastric (G) or gastroesophageal junction (GEJ) cancer.
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2023-12-25.
Status change: Not Yet Recruiting → Recruiting 2024-06-25
Trial Details
NCT Number NCT06196697
Lead Sponsor Harbin Medical University
Conditions Gastric Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma
Enrollment 50 participants
Start Date 2024-04-10
Primary Completion 2027-01 (estimated)
Study Completion 2027-03 (estimated)
Updated on ClinicalTrials.gov 2024-06-27